Log in to search using one of your social media accounts:

 

The impact of the latest echocardiographic chamber quantification recommendations on the prediction of left atrial appendage thrombus presence by transthoracic echocardiography.

CONCLUSIONS: Differentiation between normal and abnormal value enhanced the diagnostic meaning of LAVi in the aspect of higher LAAT risk. LVEF reclassification had no significant influence. PMID: 28799449 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research

Related Links:

The objective of this study is to evaluate patterns of prescription switching in non-valvular atrial fibrillation (NVAF) patients initiated on a DOAC and previously na ïve to anticoagulation (AC) therapy. Data was obtained from Truven Health MarketScan® Commercial and Medicare Supplemental database (2009 –2013). AC naïve (those without prior anticoagulant use) NVAF patients initiated on a DOAC, with 6 months of continuous health plan enrollment before and after treatment initiation and maintained on continuous therapy for a minimum of 6 months were included. Of 34,022 AC naïve NVAF patien...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
p.p1 {margin: 0.1px 0.0px 0.1px 0.3px; font: 10.0px Helvetica}60-something presents with acute onset of chest pain.His pain was accompanied by shortness of breath.  It awoke him from sleep.Here is the prehospital ECG:What do you think?The rhythm appears to be atrial fibrillation.  There are no pacing spikes and the morphology is not right for a paced rhythm.  There is a wide complex that appears to be RBBB + LAFB.  There is excessive ST depression in V1 and V2.  Where normally RBBB would manifest a large R'-wave in V3, the lead may have been placed to far lateral and, instead, there is an...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
A huge thrombus, developing after percutaneous left atrial appendage occlusion, has been successfully treated with dabigatran and aspirin as combination therapy. Although novel oral anticoagulants alone may be effective in thrombus dissolution, the association of an antiplatelet drug may safely enhance this process.
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Images in cardiology Source Type: research
CONCLUSIONS: These observations demonstrate that coagulation FXa inhibitor probably has a cardioprotective effect against pressure-overload-induced atrial remodeling. PMID: 28993090 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - Category: Cardiology Authors: Tags: J Cardiol Source Type: research
Introduction: The European Society of Cardiology guidelines on the management of atrial fibrillation (AF) advocate the use of direct oral anticoagulants (DOACs) in preference to warfarin. DOACs are also licensed for the treatment of pulmonary embolus and deep venous thrombosis. DOACs are easier to use, result in fewer intracranial haemorrhages and are just as efficacious, if not more so, in reducing the incidence of ischaemic strokes as warfarin.
Source: Europace - Category: Cardiology Source Type: research
Background: Prevention of thromboembolism is key in individuals with non-valvular atrial fibrillation (NVAF) and nonadherence to oral anticoagulant (OAC) therapy is a frequent causative factor of stroke. Many factors contribute to the complexity of medication nonadherence. Thus, education aimed at changing health behaviors must be tailored to address the unique internal motivations and information needs of those confronted with the daily choice to take a medication to prevent stroke. Delivery of tailored health education and medication reminders may be an effective way to empower individuals with NVAF and in consequence, i...
Source: Europace - Category: Cardiology Source Type: research
CONCLUSIONS: This study shows that RAS inhibitors may be effective in reducing the risk of LAAT in patients with AF through atrial reverse remodeling. PMID: 28980280 [PubMed - as supplied by publisher]
Source: Cardiology Journal - Category: Cardiology Authors: Tags: Cardiol J Source Type: research
A good percentage of patients with atrial fibrillation may be ineligible for warfarin due to increased risk of major bleeding or recurrent systemic thromboembolism. Are DOACs a viable alternative?Journal of Cardiovascular Electrophysiology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. Arch Cardiovasc Dis. 2017 Oct 02;: Authors: Dillinger JG, Aleil B, Cheggour S, Benhamou Y, Béjot Y, Marechaux S, Delluc A, Bertoletti L, Lellouche N Abstract Non-vitamin K antagonist oral anticoagulants (NOACs) - dabigatran, rivaroxaban, apixaban and edoxaban - are well established in terms of preventing stroke or systemic embolism in patients with non-valvular atrial fibrillation and high thromboembolism risk. When ...
Source: Archives of Cardiovascular Diseases - Category: Cardiology Authors: Tags: Arch Cardiovasc Dis Source Type: research
Conclusions TEE findings indicated that smoking status could be associated with thromboembolic risk in patients with AF.
Source: Journal of Arrhythmia - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Cardiology | Databases & Libraries | Heart | Study | Thrombosis